Tokyo Tape
Sign in
← Seikagaku

Quarterly report · Q3

4548.TEDINET S100SWGL
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥27.4bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥33.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥26.2bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥2.3bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥3.4bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥3.0bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥3.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥3.0bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥2.7bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.7bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥79.9bnat 2023-12-31Cons.Assets
Total assets¥75.6bnat 2023-03-31Cons.Assets
Total assets¥76.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥8.2bnat 2023-12-31Cons.Liabilities
Total liabilities¥8.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥71.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥67.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥69.8bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥16.5bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥23.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥49.512023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥10.972023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.492022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.422022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥8.882022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio89.8%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio91.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q3r_E00970-000LALreportable segmentrevenue2023-04-01 → 2023-12-31¥7.7bn
jpcrp040300-q3r_E00970-000LALreportable segmentrevenue external2023-04-01 → 2023-12-31¥7.7bn
jpcrp040300-q3r_E00970-000LALreportable segmentsegment profit2023-04-01 → 2023-12-31¥785m
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentrevenue2023-04-01 → 2023-12-31¥19.7bn
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentrevenue external2023-04-01 → 2023-12-31¥19.7bn
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.5bn
—segment totalrevenue2023-04-01 → 2023-12-31¥27.4bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥27.4bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥2.3bn
jpcrp040300-q3r_E00970-000LALreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E00970-000LALreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E00970-000LALreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentrevenue2022-04-01 → 2022-12-31¥18.0bn
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentrevenue external2022-04-01 → 2022-12-31¥18.0bn
jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
—segment totalrevenue2022-04-01 → 2022-12-31¥26.2bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥26.2bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥3.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 386
ItemContextValueUnit
Comprehensive income attributable to owners of the parentPrior1YTDDuration6471000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration5905000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember17953000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember8209000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember26162000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration26162000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember17953000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember8209000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember26162000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration26162000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember1395000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember2011000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember3407000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration3407000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember19727000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember7657000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember27384000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration27384000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember19727000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember7657000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember27384000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration27384000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E00970-000PharmaceuticalReportableSegmentsMember1543000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E00970-000LALReportableSegmentsMember785000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember2328000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating incomeCurrentYTDDuration2328000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の4の7第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第78期第３四半期（自 2023年10月1日　至 2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)生化学工業株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass